Relay Therapeutics Director Sells $300,000 Worth of Shares. Here's Why Investors Shouldn't Panic.

Chief Corporate Development Officer Peter Rahmer disclosed the sale of 40,529 shares of Relay Therapeutics (NASDAQ:RLAY) in multiple open-market transactions on Oct. 28 and Oct. 29, 2025, as detailed in the SEC Form 4 filing. The sale was worth a combined $299,900 and nearly half of it was due to company policy regarding employee stock compensation. Transaction value is based on the SEC Form 4 weighted average purchase price of $7.40; post-transaction value reflects the market close price on Oct. 29, 2025.What proportion of Peter Rahmer's direct holdings did the transaction represent?The 40,529 shares sold represented approximately 10.72% of direct holdings before the transaction as of Oct. 29, 2025, indicating a significant reduction in ownership for this event relative to typical activity.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool